Top Restaurant Stocks Defy Competition: Investment Opportunitiesby Mark Eisenberg 13.02.2024Investing in resilient restaurant stocks like Dave & Buster's, Shake Shack, Arcos Dorados, and Domino's Pizza can strengthen portfolios and ...
Arista Networks Surprises, Yet Stock Tumbles!by Mark Eisenberg 13.02.2024Arista Networks surpasses Wall Street expectations in Q4 earnings with earnings per share of $2.08 on revenue of $1.54 billion. ...
Bezos vs Musk: Richest Title Showdownby Mark Eisenberg 13.02.2024Jeff Bezos aims to reclaim the title of the world's richest person from Elon Musk by selling up to 50 ...
Coca-Cola Earnings Surge: Investors Stay Cautiousby Mark Eisenberg 13.02.2024Coca-Cola is expected to announce strong earnings despite inflation and stock slump. Sales volume has increased and revenue forecast has ...
Arm’s Stock Frenzy: The New Nvidia in AI Boom?by Terry Bingman 13.02.2024Investors are diving into options trading for Arm Holdings as the demand for AI stocks continues to rise. The surge ...
Victory Capital Soars: RBC Raises Target to $43!by Mark Eisenberg 13.02.2024RBC Capital Markets raised its price target for Victory Capital Holdings, amid the company's strong Q4 earnings and growth strategy. ...
VF Corp Surges 11.8%: Activist Investor’s Impactby Mark Eisenberg 12.02.2024Shares of VF Corp surged 11.8% after activist investor Engaged Capital gained support from the founding family. The backing may ...
Midday Market Surge: Top Gainers in Today’s Tradeby Terry Bingman 12.02.2024Stocks climb in midday trading as most sectors trend higher, led by gains in consumer discretionary, process industries, and commercial ...
Unity Software Inc. Downgrade Sparks Extended Woesby Mark Eisenberg 12.02.2024Unity Software Inc. has been downgraded to Underperform by Macquarie Equity Research. Analysts express concerns over cost-cutting measures and anticipate ...
Gilead’s $4.3B Bet on CymaBay’s Liver Drugby Mark Eisenberg 12.02.2024Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...